15/06/23 -"Defensive attributes shining through? "
15/06/23 -"Defensive attributes shining through? "
The MedTech sector, which found itself in a dilemma between the growth and value rotation throughout 2022, has experienced a significant upswing in 2023. In the midst of persistent inflation concerns in major markets and worrisome consumption patterns fueling fears of a recession, the recent rebound might indicate that quick investors are seeking refuge in the sector's reliable defensive qualities. What is our perspective on the sector's momentum? And how do valuations factor into this equation?
AlphaValue does not have nor seek any business with companies covered in AlphaValue Research paid by subscription. As a result, investors can be confident that there is no conflict of interest that could affect the objectivity of AlphaValue Research.
| Corporate broking | NO |
| Trading in corporate shares | NO |
| Analyst ownership | NO |
| Advising of corporate (strategy, marketing, debt, etc) | NO |
| Research paid for by corporate | NO |
| Provision of corporate access paid for by corporate | NO |
| Link between and a banking entity | NO |
| Brokerage activity at AlphaValue | NO |